1Ibrahim NK, Rahman Z, Valero V, et al. Phase Ⅰ study of vinorelbine and docetaxel with granulocyte colony-stimulating factor support in the treatment of metastatic breast cancer [J]. Cancer Invest, 2002,20(1): 29-37.
2Venturini M, Del Mastro L, Garrone O, et al. Phase Ⅰ, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer [ J ]. Ann Oncol, 2002,13(4): 546-552.
3Schwetz BA. From the Food and Drug Administration [J]. JAMA,2001,286(17) : 2085.
4O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracyclin-pretreated patients with advanced breast cancer: phase Ⅲ trial results [J]. J Clin Oncol, 2002,20(12): 2812-2823.
5Brugnatelli S, Danova M, De Bella MT, et al. Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study [J]. Oncology, 2002,62(1): 33-38.
6Frasci G, Comella P, D' Aiuto G, et al. Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study [J]. Ann Oncol, 2000, 11(3):367-371.
7Burris HA 3rd.Docetaxel (Taxotere) plus trasuzumab (Herceptin) in breast cancer [J]. Semin Oncol, 2001,28(1 Suppl 3) : 38-44.
8Esteva FJ, Valero V, Booser D, et al. Phase I1 study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer [J]. J Clin Oncol, 2002,20(7): 1800-1808.
9Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel [J]. J Clin Oncol, 2002, 20(6): 1456-1466.
10Estevez LG, Cuevas JM, Anton A, et al. Weekly docetaxel as neoadjuvant vhemotherapy for stage Ⅱ and Ⅲ Breast Cancer: Efficacy and Correlation with Biological Markers in a Phase Ⅱ , Multicenter Study [J]. Clin Cancer Res, 2003,9(2): 686-692.
